Review
Oncology
Christine E. Engeland, Guy Ungerechts
Summary: Measles virus is being investigated as an innovative cancer treatment that selectively replicates in and kills cancer cells. Genetic engineering can enhance tumor specificity and therapeutic efficacy, while also activating antitumor immune responses. Clinical trials have shown promising results, and future research will focus on virus engineering and combination immunotherapies to improve clinical outcomes.
Article
Biochemical Research Methods
S. Neault, S. Bossow, C. Achard, J. C. Bell, J. S. Diallo, M. F. Leber, G. Ungerechts
Summary: Oncolytic viruses (OV) have shown promise in cancer treatment, but the host's immune response limits their effectiveness. This study introduces a novel pseudotyping platform that allows for the exchange of the viral envelope, making the OV less susceptible to pre-existing antibodies and potentially improving therapeutic outcomes.
JOURNAL OF VIROLOGICAL METHODS
(2022)
Article
Immunology
William S. Probert, Rosie Glenn-Finer, Alex Espinosa, Cynthia Yen, Lauren Stockman, Kathleen Harriman, Jill K. Hacker
Summary: In 2019, the United States saw the highest number of measles importations and cases in the post-elimination era, with more than a quarter of the cases entering through California. Measles surveillance efforts in California discovered 26 importations, 6 outbreaks, and 72 cases, highlighting the importance of maintaining appropriate vaccination status and a strong surveillance system to prevent outbreaks and preserve measles elimination status.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Virology
Sophie C. Anker, Marie G. Szczeponik, Jan Dessila, Katia Dittus, Christine E. Engeland, Dirk Jaeger, Guy Ungerechts, Mathias F. Leber
Summary: Virotherapy is being investigated as a promising form of cancer immunotherapy, but its anti-tumor potency needs improvement. One limitation is the activation of antiviral defense pathways by tumor cells, which hinders the replication efficiency of oncolytic viruses. This study developed a universal expression cassette for artificial microRNAs that can suppress genes of interest, potentially improving the effectiveness of virotherapy.
Article
Microbiology
Miguel Angel Munoz-Alia, Rebecca A. Nace, Alexander Tischer, Lianwen Zhang, Eugene S. Bah, Matthew Auton, Stephen J. Russell
Summary: The development of MeV-Stealth, a modified measles virus strain, has shown efficient targeting and lysis of CD46-expressing cancer cells in mouse models. This virus demonstrates oncolytic properties and evasion of inhibition by human measles-immune serum, making it a potential alternative to current oncolytic measles virus strains in treating measles-immune cancer patients.
Article
Biochemistry & Molecular Biology
Daniel Loewe, Hauke Dieken, Tanja A. Grein, Denise Salzig, Peter Czermak
Summary: The downstream purification of measles virus is challenging, but the combination of ultrafiltration and diafiltration can recover a certain amount of infectious virus particles.
Article
Oncology
Marion Grard, Mohamed Idjellidaine, Atousa Arbabian, Camille Chatelain, Laurine Berland, Chantal Combredet, Soizic Dutoit, Sophie Deshayes, Virginie Dehame, Nathalie Labarriere, Delphine Fradin, Nicolas Boisgerault, Christophe Blanquart, Frederic Tangy, Jean-Francois Fonteneau
Summary: Antitumor virotherapy uses oncolytic viruses to induce tumor cell lysis and stimulate the antitumor immune response. In this study, a modified measles virus expressing the cancer/testis antigen NY-ESO-1 showed similar oncolytic activity to the wild-type virus but induced faster cell lysis. The modified virus also successfully induced NY-ESO-1 expression and presentation in melanoma cells and dendritic cells, leading to the activation of NY-ESO-1-specific T cells.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Biotechnology & Applied Microbiology
Almohanad A. Alkayyal, Manar Darwish, Reham Ajina, Saleh Y. Alabbas, Mohammed A. Alotaibi, Abeer Alsofyani, Maha Bokhamseen, Maumonah Hakami, Omar A. Albaradie, Abdulaziz M. Moglan, Sharif Hala, Abdullah Faisal Alsahafi, Samer Zakri, Adnan Almuzaini, Khamis Alsharari, Feras Kaboha, Mustafa Y. Taher, Haggag S. Zein, Fayhan Alroqi, Ahmad Bakur Mahmoud
Summary: The COVID-19 pandemic has created an urgent need for safe and cost-effective vaccines to control outbreaks globally. In this study, the VSV-51M oncolytic virus platform was repurposed to express the spike receptor-binding domain (RBD) antigen to combat SARS-CoV-2. The VSV-51M-RBD vaccine demonstrated successful expression of RBD, induced anti-RBD responses without compromising the virus, and showed potential as a safe and effective alternative or complementary platform to current COVID-19 vaccines.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2023)
Article
Endocrinology & Metabolism
Hongyun Zhao, Da Teng, Lifeng Yang, Xincheng Xu, Jiajia Chen, Tengjia Jiang, Austin Y. Feng, Yaqing Zhang, Dennie T. Frederick, Lei Gu, Li Cai, John M. Asara, Marina Pasca di Magliano, Genevieve M. Boland, Keith T. Flaherty, Kenneth D. Swanson, David Liu, Joshua D. Rabinowitz, Bin Zheng
Summary: This study reveals that itaconate, produced by myeloid-derived suppressor cells (MDSCs), acts as an immune checkpoint metabolite to suppress CD8(+) T cells. Inhibition of IRG1 may enhance anti-tumour immunity and improve the efficacy of immune checkpoint blockade. These findings have implications for understanding immune surveillance and developing new strategies for cancer treatment.
Article
Immunology
Maud Wilhelm, Amandeep Kaur, Marion Wernli, Hans H. Hirsch
Summary: Using synthetic 27mer-long BKPyV peptides, different types of antigen-presenting cells, and CD4 T cells, BKPyV-specific CD8 T cell responses were expanded, providing a novel approach for vaccination and adoptive T-cell therapies for patients before and after kidney transplantation.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Review
Virology
Nusrat Jahan, Shanawaz M. Ghouse, Robert L. Martuza, Samuel D. Rabkin
Summary: oHSV, modified to target cancer cells while sparing normal cells, induces anti-tumor immune responses and has shown efficacy in both preclinical models and clinical trials. Recent advancements, including FDA approval for melanoma treatment and combination with other immunotherapeutic agents, have invigorated the field of oncolytic viruses.
Article
Virology
Ching-Hsuan Liu, Chen-Jei Tai, Yu-Ting Kuo, Shen-Shong Chang, Liang-Tzung Lin
Summary: Hepatocellular carcinoma (HCC) is a challenging cancer to treat and requires more effective therapeutic strategies. In this study, the combination of oncolytic measles virus (MV) and natural triterpenoid compound ursolic acid (UA) showed synergistic cytotoxic effects on HCC cells, including those with hepatitis B virus (HBV) or hepatitis C virus (HCV) replication. The combination induced enhanced apoptosis, increased oxidative stress, and dysregulation of the mitochondria-dependent pathway. These findings highlight the potential of the MV and UA combination as a treatment strategy for HCC.
Review
Immunology
Cao-Sang Truong, So Young Yoo
Summary: Therapeutic cancer vaccines induce long-term immune response by targeting tumor-associated antigens, reducing adverse effects. Vaccinia virus (VV) as an oncolytic virus has promising potential in lung cancer treatment. Non-small cell lung cancer is highly responsive to immunotherapy.
Article
Immunology
Huy Quang Quach, Inna G. Ovsyannikova, Diane E. Grill, Nathaniel D. Warner, Gregory A. Poland, Richard B. Kennedy
Summary: The study found that even in a highly vaccinated population, a significant proportion of adults lack immunity to measles, with gender and age influencing the immune response.
Article
Oncology
Ching-Hsuan Liu, Shu Hui Wong, Chen-Jei Tai, Cheng-Jeng Tai, Yu-Chi Pan, Hsue-Yin Hsu, Christopher D. Richardson, Liang-Tzung Lin
Summary: Ursolic acid (UA) and its nanoparticles enhance oncolytic measles virus (MV) activity against breast cancer cells, inducing apoptosis and showing potential synergistic anticancer effects.
Article
Oncology
Beatrice Vanbervliet-Defrance, Tiphaine Delaunay, Thomas Daunizeau, Vahan Kepenekian, Olivier Glehen, Kathrin Weber, Yann Estornes, Audrey Ziverec, Leila Djemal, Marion Delphin, Sylvie Lantuejoul, Guillaume Passot, Marc Gregoire, Olivier Micheau, Christophe Blanquart, Toufic Renno, Jean-Francois Fonteneau, Serge Lebecque, Karene Mahtouk
Article
Oncology
Tiphaine Delaunay, Carole Achard, Nicolas Boisgerault, Marion Grard, Tacien Petithomme, Camille Chatelain, Soizic Dutoit, Christophe Blanquart, Pierre-Joseph Royer, Stephane Minvielle, Lisa Quetel, Clement Meiller, Didier Jean, Delphine Fradin, Jaafar Bennouna, Antoine Magnan, Laurent Cellerin, Frederic Tangy, Marc Gregoire, Jean-Francois Fonteneau
JOURNAL OF THORACIC ONCOLOGY
(2020)
Article
Oncology
Virginie Vignard, Maureen Labbe, Nadege Marec, Gwennan Andre-Gregoire, Nicolas Jouand, Jean-Francois Fonteneau, Nathalie Labarriere, Delphine Fradin
CANCER IMMUNOLOGY RESEARCH
(2020)
Article
Oncology
Joelle S. Nader, Jordan Guillon, Coralie Petit, Alice Boissard, Florence Franconi, Stephanie Blandin, Sylvia Lambot, Marc Gregoire, Veronique Verriele, Beatrice Nawrocki-Raby, Philippe Birembaut, Olivier Coqueret, Catherine Guette, Daniel L. Pouliquen
Letter
Oncology
Didier Jean, Tiphaine Delaunay, Clement Meiller, Nicolas Boisgerault, Marion Grard, Stefano Caruso, Christophe Blanquart, Emanuela Felley-Bosco, Jaafar Bennouna, Frederic Tangy, Marc Gregoire, Jean-Francois Fonteneau
JOURNAL OF THORACIC ONCOLOGY
(2020)
Article
Oncology
Thibaut Blondy, Senan Mickael d'Almeida, Tina Briolay, Julie Tabiasco, Clement Meiller, Anne-Laure Chene, Laurent Cellerin, Sophie Deshayes, Yves Delneste, Jean-Francois Fonteneau, Nicolas Boisgerault, Jaafar Bennouna, Marc Gregoire, Didier Jean, Christophe Blanquart
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
Editorial Material
Medicine, Research & Experimental
Tacien Petithomme, Marion Grard, Jean-Francois Fonteneau, Nicolas Boisgerault
M S-MEDECINE SCIENCES
(2020)
Article
Oncology
Suna Sun, Francesca Frontini, Weihong Qi, Ananya Hariharan, Manuel Ronner, Martin Wipplinger, Christophe Blanquart, Hubert Rehrauer, Jean-Francois Fonteneau, Emanuela Felley-Bosco
Summary: Early events in mesothelioma development involve increased levels of editing in double-stranded RNA (dsRNA). Expression of endogenous retroviruses (ERV) contributes to dsRNA formation and type-I interferon signaling. These findings may have implications for early diagnosis and treatment strategies.
Review
Oncology
Marion Grard, Camille Chatelain, Tiphaine Delaunay, Elvire Pons-Tostivint, Jaafar Bennouna, Jean-Francois Fonteneau
Summary: The review discusses the potential impact of homozygous deletion of IFN I genes on thoracic cancers therapy, advocating for better consideration of this genetic alteration in patient monitoring.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell & Tissue Engineering
Marine Charrier, Judith Lorant, Rafael Contreras-Lopez, Gautier Tejedor, Christophe Blanquart, Blandine Lieubeau, Cindy Schleder, Isabelle Leroux, Sophie Deshayes, Jean-Francois Fonteneau, Candice Babarit, Antoine Hamel, Armelle Magot, Yann Pereon, Sabrina Viau, Bruno Delorme, Patricia Luz-Crawford, Guillaume Lamirault, Farida Djouad, Karl Rouger
Summary: The study demonstrates that hMuStem cells possess an immunosuppressive phenotype and can inhibit T-cell proliferation and cytotoxic response while promoting the generation of regulatory T cells through both direct contact and secretion of soluble factors. The secretion profile of hMuStem cells is shown to be superior to that of BM-MSCs. These findings reinforce the candidacy of hMuStem cells as therapeutic agents for MDs.
STEM CELL RESEARCH & THERAPY
(2022)
Review
Cell Biology
Elvire Pons-Tostivint, Alexandre Lugat, Jean-Francois Fontenau, Marc Guillaume Denis, Jaafar Bennouna
Summary: The STK11/LKB1 gene codes for an important kinase involved in energy-related cellular processes, and its inactivation can lead to the progression of lung cancer and impact the tumor immune environment. Descriptive epidemiology, co-occurring genomic alterations, and prognostic impact for lung cancer patients are discussed, as well as the effects of STK11/LKB1 alterations on the immune system and response to immune checkpoint inhibitors in pre-clinical models and lung cancer cohorts.
